Skip to Content

'
Mariana Chavez Mac Gregor, MD, MSC

Present Title & Affiliation

Primary Appointment

Assistant Professor, Tenure track, Department of Health Services Research, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2004 Netherlands Institute of Health and Sciences, Rotterdam, Netherlands, MSc, Clinical Epidemiology
2003 Medical School at Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, MD, Medicine

Postgraduate Training

7/2008-6/2011 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2006-6/2008 Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO

Board Certifications

11/2011 Medical Oncology
2008 Internal Medicine

Honors and Awards

2011 Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center
2011 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2011 SWOG Young Investigator, SWOG
2010 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, M.D. Anderson Cancer Center
2010 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2010 Selected for participation at the AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado
2009 AACR Minority Scholar, Susan G. Komen for the Cure
2009 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, M.D. Anderson Cancer Center
2009 ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2009 ASCO Merit Award
2008 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, M.D. Anderson Cancer Center
2008 Kipnis-Daughaday Teaching Award, Washington University School of Medicine
2006 Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine
2006 Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO.
2004 NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute
2003 Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology in Mexico
2002 Achievement Medical Student Award, Universidad Nacional Autónoma de México
2001 Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México

Professional Memberships

American Association for Cancer Research
Associate Member, 2009-present
American Society of Clinical Oncology
Associate Member, 2008-present
Mexican Society of Senology
Member, 2001-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-MacGregor M. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735-44, 3/2014. e-Pub 1/2014. PMCID: PMC3940536.
2. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Ann Surg Oncol 21(3):704-16, 3/2014. e-Pub 2/2014. PMID: 24515565.
3. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys 88(3):553-64, 3/2014. PMID: 24521674.
4. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol. e-Pub 2/2014. PMID: 24516019.
5. Chavez-MacGregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Symmans WF, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. e-Pub 12/2013. PMID: 24296856.
6. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-Macgregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. e-Pub 12/2013. PMID: 24351399.
7. Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, Chavez-MacGregor M, Smith BD, Kuerer HM. Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery. Ann Surg Oncol. e-Pub 8/2013. PMID: 23959054.
8. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-MacGregor M, Smart M, Gonzalez-Angulo AM. Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer. Clin Breast Cancer. e-Pub 6/2013. PMID: 23810431.
9. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer. J Clin Oncol. e-Pub 6/2013. PMID: 23796991.
10. Chavez-MacGregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119(9):1611-7, 5/2013. e-Pub 1/2013. PMID: 23341341.
11. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-MacGregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 24(4):909-16, 4/2013. e-Pub 11/2012. PMCID: PMC3603436.
12. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. e-Pub 6/2012. PMCID: PMC3461089.
13. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-MacGregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. SpringerPlus 2(409), 2013.
14. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer 4(7):549-56, 2013. e-Pub 8/2013. PMCID: PMC3753529.

Invited Articles

1. Chavez-MacGregor M, Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10(2):75-6, 2/2013. e-Pub 1/2013. PMID: 23296111.

Abstracts

1. Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez-MacGregor M, Yi M, Hunt KK, Strom EA. Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer. Ann Surg oncol, 09/24/2014. e-Pub 9/2014. PMID: 25249256.
2. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?. Ann Surg Oncol 21(8):2468-73, 05/20/2014, 8/2014. e-Pub 5/2014. PMID: 24841348.
3. Mariana Chavez-Mac Gregor, Napa Parinyanitikul, Elizabeth Ann Mittendorf, Xiudong Lei, Hong Zhang, Aman Buzdar, Kelly Hunt, Gabriel N. Hortobagyi, Vicente Valero, Ana M. Gonzalez-Angulo. Effect of Adjuvant Trastuzumab (T) Among Patients Treated with Neoadjuvant T-based Chemotheraphy. J Clin Oncol 32:5s (#644), 2014.
4. Aditya Bardia, Shanu Modi, Mariana Chavez-Mac Gregor, Muaiad Kittaneh, Alyssa J. Marino, Alessandro Matano, Suraj Bhansali, Becker Hewes, Javier Cortes. Phase Ib/II Study of LEE011, Everolimus, and Exemestane in Postmenopausal Women with ER+/HER2-Metastatic Breast Cancer. J Clin Oncol 32:5s (#535), 2014.
5. Kogawa T, Fouad TM, Wei C, El-Zein RA, Masuda H, Chavez-Mac-Gregor M, Melhem-Bertrandt A, Litton JK, Brewster AM, Alvarez RH, Hortobagyi GN, Vicente V, Ueno NT, Theriault RL. Association between body mass index change during neoadjuvant chemotherapy and pathologic complete response and overall survival in patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
6. Masuda H, Chavez-Mac Gregor M, Liu DD, Alvarez RH, Krishnamurthy S, Lucci A, Woodward W, Gildy B, Mittendorf EA, DeSnyder SM, Shen Y, Willey JS, Hortobagyi GN, Valero V, Ueno NT. Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy. Proceedings from 2013 San Antonio Breast Cancer Symposium, 12/2013.
7. Chavez-Mac Gregor M, Lei X, Litton JK, Melhem-Bertrand A, Giordano SH, Masuda H, Ueno N, Gabriel HN, Valero V. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. Proceedings fron 2013 San Antonio Breast Cancer Symposium, 12/2013.
8. Pusztai L, Mattair D, Ueno NT, Valero V, Moulder SL, Murray JL, Alvarez RH, Chavez-Mac Gregor M, Santiago L, Avritscher R, Sahin AA, Hortobagyi GN, Symmand WF, Meric-Bernstam F, Burton EM, Gonzalez-Angulo AM. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. J Clin Oncol(31) (#532), 2013.
9. Chavez-Mac Gregor M, Zhang N, Niu J, Elting LS, Buchholz TA, Valero V, Giordano SH. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older breast cancer patients. JClin Oncol 31 (#6330), 2013.
10. Chavez-MacGregor M, Parinyanitikul N, Lei X, Mittendorf E, Litton JK, Woodward W, Zhang A; Gonzalez-Angulo AM. Changes in breast cancer subtype between primary tumor and residual disease after neoadjuvant systemic chemotherapy. Proceedings from European CanCer Organisation (ECCO) – ESMO Meeting (#2065), 2013.
11. Gagliato DD, Gonzalez-Angulo AM, Aiudong L, Giordano SH, Theriault RL, Valero V, Hortobagyi GN, Chavez-Mac Gregor M. Impact of delaying initiation of adjuvant chemotherapy in breast cancer patients. J Clin Oncol 31 (#1022), 2013.
12. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Mac Gregor M, Smart ML, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple-receptor negative breast cancer. J Clin Oncol (#e12002), 2013.
13. Chavez-Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott A, Paik S, Lew D, Bandos H, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207. J Clin Oncol 31 (#TPS657), 2013.
14. Kogawa T, Fouad T, Liu D, Shen Y, Masuda H, Chavez-MacGregor M, Alvarez RH, Valero V, Hortobagyi GN, Ueno NT. Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer. Proceeding from European CanCer Organisation (ECCO) – ESMO Meeting (#1910), 2013.

Letters to the Editor

1. Litton J, Buzdar A, Chavez-MacGregor M, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 6/2013. PMID: 23769223.

Last updated: 12/8/2014